HER2-POSITIVE ADVANCED BREAST CANCER
Clinical trials for HER2-POSITIVE ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug BBO-10203 enters first human trials
Disease control Recruiting nowThis early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…
Matched conditions: HER2-POSITIVE ADVANCED BREAST CANCER
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for advanced breast cancer: TQB2930 enters phase 3 trial
Disease control Recruiting nowThis phase 3 trial is testing a new drug called TQB2930, given with chemotherapy, for people with HER2-positive advanced breast cancer who have already tried at least two prior anti-HER2 treatments. The study compares TQB2930 plus chemo to the standard drug trastuzumab plus chemo…
Matched conditions: HER2-POSITIVE ADVANCED BREAST CANCER
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
PET scan could predict best drug sequence for advanced breast cancer
Disease control Recruiting nowThis study tests whether a special PET scan (HER2-PET) can help doctors decide which drug to use next in people with advanced HER2-positive breast cancer whose cancer has stopped responding to the drug trastuzumab deruxtecan (T-DXd). About 87 participants will get the scan and be…
Matched conditions: HER2-POSITIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Jules Bordet Institute • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for advanced cancer: experimental drug targets HER2
Disease control Recruiting nowThis early-stage trial tests a new drug called SIBP-A17 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein called HER2 found on some cancer cells. The study aims to find the safest dose and understand how the drug works…
Matched conditions: HER2-POSITIVE ADVANCED BREAST CANCER
Phase: PHASE1 • Sponsor: Shanghai Institute Of Biological Products • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Breast cancer drug schedule showdown: continuous vs. intermittent dosing
Disease control Recruiting nowThis study compares two ways of taking the drug pyrotinib for people with HER2-positive advanced breast cancer: taking it every day (continuous) or taking breaks (intermittent). The goal is to see which schedule works better and has fewer side effects. About 186 adults whose canc…
Matched conditions: HER2-POSITIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Wenjin Yin • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New scan may personalize breast cancer therapy
Knowledge-focused Recruiting nowThis study is testing whether a special PET scan (HER2-PET) can predict how well the drug T-DXd works in people with advanced breast cancer. About 100 participants with HER2-positive or HER2-low breast cancer will get the scan before treatment. The goal is to see if the scan can …
Matched conditions: HER2-POSITIVE ADVANCED BREAST CANCER
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Can switching breast cancer drugs improve outcomes? new study watches real-world results.
Knowledge-focused Recruiting nowThis study observes 100 people in Korea with advanced HER2-positive breast cancer who take a drug called T-DM1 right after another drug, T-DXd, stops working. Researchers will track how long the cancer stays controlled and how well patients respond. The goal is to learn if this d…
Matched conditions: HER2-POSITIVE ADVANCED BREAST CANCER
Sponsor: Seoul National University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC